Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204262) titled 'Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma' on Sept. 24.
Study Type: Observational
Primary Sponsor: Xu Yong, MD
Condition:
Liver Cancer
Intervention:
Combination Product: Molecular Targeted Therapy (TKI / anti-VEGF antibody) PD-(L)1 Inhibitor Immunotherapy Interventional Therapy (TACE / HAIC)
Recruitment Status: Not recruiting
Date of First Enrollment: January 1, 2018
Target Sample Size: 379
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07204262
Published by HT Digital Content Services with permission from Health Daily Digest....